TaiMed Biologics (4147) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.016x

Based on the latest financial reports, TaiMed Biologics (4147) has a cash flow conversion efficiency ratio of 0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$58.88 Million ≈ $1.86 Million USD) by net assets (NT$3.68 Billion ≈ $115.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4147 market cap for the company's overall valuation and market capitalisation.

TaiMed Biologics - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how TaiMed Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data.

TaiMed Biologics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TaiMed Biologics ranked by their cash flow conversion efficiency. Explore TaiMed Biologics (4147) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Raydium Semi-Conductor TW:3592	-0.003x
Zhejiang Gongdong Medical Technology Co Ltd SHG:605369	0.034x
JinkoSolar Holding Company Limited NYSE:JKS	-0.268x
MOIL Limited NSE:MOIL	0.050x
PDS Limited NSE:PDSL	0.319x
Lu Thai Textile Co Ltd SHE:000726	0.012x
Nexpoint Residential Trust Inc NYSE:NXRT	0.084x
Harson Trading China Co Ltd SHG:603958	0.049x

Annual Cash Flow Conversion Efficiency for TaiMed Biologics (2015–2025)

The table below shows the annual cash flow conversion efficiency of TaiMed Biologics from 2015 to 2025. View 4147 live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$3.86 Billion ≈ $121.54 Million	NT$191.14 Million ≈ $6.02 Million	0.050x	+152.52%
2024-12-31	NT$4.02 Billion ≈ $126.74 Million	NT$-379.55 Million ≈ $-11.96 Million	-0.094x	-845.68%
2023-12-31	NT$2.57 Billion ≈ $80.85 Million	NT$-25.60 Million ≈ $-806.57K	-0.010x	+95.52%
2022-12-31	NT$2.71 Billion ≈ $85.53 Million	NT$-605.21 Million ≈ $-19.07 Million	-0.223x	-210.36%
2021-12-31	NT$2.94 Billion ≈ $92.67 Million	NT$-211.28 Million ≈ $-6.66 Million	-0.072x	-21.50%
2020-12-31	NT$3.42 Billion ≈ $107.62 Million	NT$-201.94 Million ≈ $-6.36 Million	-0.059x	+67.65%
2019-12-31	NT$3.59 Billion ≈ $112.99 Million	NT$-655.31 Million ≈ $-20.65 Million	-0.183x	-42.60%
2018-12-31	NT$4.08 Billion ≈ $128.56 Million	NT$-522.86 Million ≈ $-16.47 Million	-0.128x	-6.49%
2017-12-31	NT$4.29 Billion ≈ $135.23 Million	NT$-516.48 Million ≈ $-16.27 Million	-0.120x	-229.21%
2016-12-31	NT$4.71 Billion ≈ $148.51 Million	NT$-172.29 Million ≈ $-5.43 Million	-0.037x	+59.87%
2015-12-31	NT$4.90 Billion ≈ $154.37 Million	NT$-446.26 Million ≈ $-14.06 Million	-0.091x	--

About TaiMed Biologics

TWO:4147 Taiwan Biotechnology

Market Cap

$536.45 Million

NT$17.03 Billion TWD

Market Cap Rank

#11998 Global

#436 in Taiwan

Share Price

NT$62.90

Change (1 day)

+0.64%

52-Week Range

NT$47.10 - NT$77.40

All Time High

NT$341.00